heart failure

Federal program aimed at reducing readmissions raises concernsA new study has shocking findings about death rates in heart failure patients enrolled in the Hospital Readmissions Reduction Program.
CE: Heart failure: Pumping up Knowledge, Circulating New Approaches
CE: Heart failure: Pumping up Knowledge, Circulating New Approaches
How to target high-risk populations with behavioral healthHere are four of the top benefits of incorporating behavioral health management into care management plans for members with chronic conditions.
New combo therapy for chronic heart failureEntresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.
Entresto may prevent death in some heart failure patientsTimely and broad use of Entresto could prevent or postpone more than 28,000 US deaths per year among HFrEF patients, according to research in JAMA Cardiology.
Novartis signs on to value-based pricing for EntrestoHospitalizations represent up to 80 percent of the direct medical costs of heart failure; reducing heart failure hospitalizations can help bring down overall healthcare costs.
Telemonitoring of heart failure patients reduces readmissionsStudy demonstrates how new technology can drive higher value healthcare for heart failure patients.
Pre-op anticoagulation reduces VTE risk in cancer patientsResearchers found that rates of DVT and PE were significantly lower among patients who received preoperative chemoprophylaxis than in those who did not.
Insurers set performance-based price for heart drugIn one of the few arrangements of its kind, Cigna Corp and Aetna Inc. struck a deal with Novartis for a performance-based price for its heart failure drug, Entresto.
Heart drug improves life expectancyThere is some good news for heart failure patients’ life expectancy, in a recent study published in the New England Journal of Medicine.